Clinical Trials Directory

Trials / Conditions / Stage III Primary Peritoneal Cancer AJCC v8

Stage III Primary Peritoneal Cancer AJCC v8

12 registered clinical trials studyying Stage III Primary Peritoneal Cancer AJCC v8 — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingAn Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in S
NCT06855706
Roswell Park Cancer InstituteN/A
WithdrawnSpecialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients W
NCT03735589
Roswell Park Cancer InstitutePhase 1 / Phase 2
WithdrawnZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
NCT05368506
OHSU Knight Cancer InstituteEARLY_Phase 1
Active Not RecruitingTesting the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage
NCT05276973
National Cancer Institute (NCI)Phase 1
RecruitingHyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Tr
NCT05415709
Ohio State University Comprehensive Cancer CenterEARLY_Phase 1
RecruitingPhase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa
NCT05092373
M.D. Anderson Cancer CenterPhase 1
Active Not RecruitingNiraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa
NCT04673448
University of WashingtonPhase 1
Active Not RecruitingTesting the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea
NCT04616534
National Cancer Institute (NCI)Phase 1
Active Not RecruitingLetrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian
NCT04095364
NRG OncologyPhase 3
Active Not RecruitingOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cance
NCT03943173
M.D. Anderson Cancer CenterEARLY_Phase 1
Active Not RecruitingModified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistan
NCT03907527
Precigen, IncPhase 1
Active Not RecruitingGene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY
NCT02650986
Roswell Park Cancer InstitutePhase 1 / Phase 2